Advertisement

Topics

Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer

20:00 EDT 7 Jul 2019 | BioSpace

Median progression-free survival for patients receiving Braftovi Triplet was 4.3 months compared to 1.5 months.

Original Article: Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer

NEXT ARTICLE

More From BioPortfolio on "Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer"

Advertisement
Quick Search
Advertisement
Advertisement